I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Osimertinib	
Re-assessmen	NSCLC – first line trequired after 4 months (tick boxes where appropriate)
and or or and on an analysis of an analysis o	Patient has locally advanced or metastatic, incurable, non-squamous non-small cell lung cancer (NSCLC) Patient is treatment naïve Patient has received prior treatment in the adjuvant setting and/or while awaiting EGFR results The patient has discontinued gefitinib or erlotinib due to intolerance and The cancer did not progress while on gefitinib or erlotinib There is documentation confirming that the cancer expresses activating mutations of EGFR Patient has an ECOG performance status 0-3 Baseline measurement of overall tumour burden is documented clinically and radiologically
Prerequisites Respondence Resp	trequired after 6 months (tick box where appropriate) onse to or stable disease with treatment in target lesions has been determined by comparable radiologic assessment following the most at treatment period NSCLC – second line at required after 4 months
	(tick boxes where appropriate)
and and and	Patient has locally advanced or metastatic, incurable, non-squamous non-small cell lung cancer (NSCLC) Patient has an ECOG performance status 0-3 The patient must have received previous treatment with erlotinib or gefitinib There is documentation confirming that the cancer expresses T790M mutation of EGFR following progression on or after erlotinib or gefitinib
	The treatment must be given as monotherapy
and	Baseline measurement of overall tumour burden is documented clinically and radiologically
Re-assessmen Prerequisites	ON – NSCLC – second line It required after 6 months (tick box where appropriate) onse to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment d